The issuance of 64,668 freely tradable common shares to a single holder (Streeterville) at a $2M market cap represents significant potential selling pressure. Monitor for Streeterville's Form 144 filings or 13D/G amendments indicating share sales. The repeated adjournment of the annual meeting suggests unresolved shareholder voting issues that could lead to further disclosure.
Price Chart
Executive Summary
Jaguar Health entered into two exchange agreements with Streeterville Capital, converting 7.92 shares of Series Q Preferred Stock into 64,668 common shares issued without restrictive legends under Section 3(a)(9). Separately, the company further adjourned its 2026 Annual Meeting to June 8, 2026, to allow stockholders more time to review supplemental proxy materials. The exchange eliminates preferred stock overhang but immediately dilutes existing common shareholders at a micro-cap company with a $2M market cap.
Key Facts
- Issued 31,958 common shares to Streeterville on May 26, 2026 in exchange for 3.72 Series Q Preferred shares.
- Issued 32,710 common shares to Streeterville on June 1, 2026 in exchange for 4.2 Series Q Preferred shares.
- Total of 64,668 common shares issued for 7.92 Series Q Preferred shares across both exchanges.
- Shares issued without restrictive legends and are immediately tradable (Free Trading).
- Annual Meeting further adjourned to June 8, 2026 after being reconvened on June 2, 2026.
- Market cap is approximately $2M, making the dilution highly material relative to outstanding shares.
Financial Impact
64,668 common shares issued in exchange for 7.92 Series Q Preferred shares; no cash consideration received. At a $2M market cap, this represents a material dilution event.
Risk Factors
- Immediate dilution from 64,668 new common shares relative to a $2M market cap.
- Streeterville may sell the unrestricted shares, creating downward price pressure.
- Annual meeting adjournment signals potential governance or voting complications.
- No new cash raised — the exchange is purely liability management, not growth capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-253506 |
| Document: d95782dex102.htm | 0001193125-26-253506 |
| Document: d95782dex101.htm | 0001193125-26-253506 |
| Document: 0001193125-26-253506-index-headers.html | 0001193125-26-253506 |
| Document: 0001193125-26-253506-index.html | 0001193125-26-253506 |
| Document: 0001193125-26-253506.txt | 0001193125-26-253506 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | S-3 | $2.04 | awaiting T+60 | — | $2.37 (−16.18%) |
Oct 8, 2026 18d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.37 (+50.52%) |
Oct 5, 2026 21d ago | 8-K | $4.73 | awaiting T+60 | — | $2.37 (+49.89%) |
Sep 28, 2026 28d ago | 8-K | $6.02 | awaiting T+60 | — | $2.37 (+60.63%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.37 (+69.22%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 21, 2026 5w ago | 8-K | $34.46 | awaiting T+60 | — | $2.37 (−93.12%) |
Sep 15, 2026 5w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.37 (−955.21%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.37 (+77.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers